Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness...

Area of Science:

• Endocrinology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is a leading cause of death in type 2 diabetes patients.
• The impact of glucose-lowering medications on CVD outcomes in low-risk type 2 diabetes patients remains unclear.

Purpose of the Study:

• To compare cardiovascular outcomes among patients with type 2 diabetes and low cardiovascular risk treated with insulin glargine, glimepiride, liraglutide, or sitagliptin.
• To evaluate the efficacy of different glucose-lowering agents in preventing major adverse cardiovascular events (MACE).

Main Methods:

• The Glycemia Reduction Approaches in Type 2 Diabetes (GRADE) study randomized 5047 participants to four treatment groups.
• Participants were followed for a median of 5 years, with prespecified analyses of MACE-3, MACE-4, MACE-5, MACE-6, and heart failure hospitalizations.
• Cox proportional hazards models and proportional rate models were used for statistical analysis.

Main Results:

• No significant differences in the first occurrence of MACE-3, MACE-4, MACE-5, or MACE-6 were observed between treatment groups.
• Liraglutide treatment was associated with a significantly lower risk of MACE-5, MACE-6, and hospitalization for heart failure compared to other groups combined.
• Recurrent MACE-6 events were significantly higher in the glimepiride and sitagliptin groups compared to the liraglutide group.

Conclusions:

• Liraglutide may reduce cardiovascular event risk in type 2 diabetes patients with low baseline cardiovascular risk.
• This comparative effectiveness study suggests liraglutide as a potentially beneficial treatment option for this patient group.